Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Haematological Malignancy|Acute Myeloid Leukemia|Non Hodgkin Lymphoma|Multiple Myeloma|Higher-risk Myelodysplastic Syndrome|Peripheral T Cell Lymphoma
DRUG: CCS1477|DRUG: Pomalidomide|DRUG: Dexamethasone|DRUG: Azacitidine|DRUG: Venetoclax
Incidence of treatment-related adverse events, Treatment-related adverse events and serious adverse events, Up to 12 months|Incidence of laboratory abnormalities, Laboratory abnormalities characterised by type, frequency, severity and timing, Up to 12 months
Response rate, Defined as number of patients who have a response according to

* RECIL criteria (NHL)
* IMWG criteria (Multiple myeloma)
* ELN recommendations 2017 (AML), Up to 12 months|Duration of Response, Defined as the time from start of treatment until disease progression, Up to 12 months|AUC of CCS1477, Area under the plasma concentration-time curve (AUC) from time 0 to the time of the last measurable concentration of CCS1477, 35 days|Cmax of CCS1477, Maximum observed plasma concentration (Cmax) of CCS1477, 35 days
This includes patients with Peripheral T-cell lymphoma.